Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

Conditions

• Multiple Myeloma

Interventions

• PROCEDURE: Biospecimen Collection
• PROCEDURE: Bone Marrow Aspirate
• PROCEDURE: Bone Marrow Biopsy
• PROCEDURE: Computed Tomography
• DRUG: Ixazomib Citrate
• DRUG: Lenalidomide
• OTHER: Placebo Administration
• PROCEDURE: Positron Emission Tomography
• OTHER: Quality-of-Life Assessment
• OTHER: Questionnaire Administration

Sponsor

National Cancer Institute (NCI)